欢迎来到OAJRC平台!

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Medical Research Frontier. 2020; 4: (1) ; 1-6 ; DOI: 10.12208/j.imrf.20200001.

Research progress in the treatment of Advanced Hepatocellulr Carcinoma with Apatinib Mesylate
甲磺酸阿帕替尼片治疗晚期肝癌的研究进展

作者: 江慢迪, 孙志为*,

云南省第一人民医院 云南昆明

*通讯作者: 孙志为,单位:云南省第一人民医院 云南昆明;

发布时间: 2020-12-30 总浏览量: 264

摘要

甲磺酸阿帕替尼为中国研发的抗血管生成靶向药,抑制VEGFR-2,破坏了其与酪氨酸激酶ATP间的结合,导致酪氨酸激酶无法被激活,达到阻止恶性肿瘤血管形成的功效。此文总体概述与阿帕替尼治疗末期肝癌相关的基本和临床科学研究工作的现况与发展,使之后的研究有所参照。

关键词: 阿帕替尼;原发性肝癌;现状及进展

Abstract

Apatinib Mesylate, an anti-angiogenic target drug developed inChina, inhibits VEGFR-2 and destroys its binding to tyrosine kinase AT-P, thus preventing tyrosine kinase from being activated and preventing malignant tumor angiogenesis. This article gives a general overview of the current status and development of basic and clinical research relat-ed to the treatment of advanced liver cancer with Apatinib, so as to provide references for future studies.

Key words: Apatinib; Hepatocellulr Carcinoma; Study and Development

参考文献 References

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

[34]

[35]

引用本文

江慢迪, 孙志为, 甲磺酸阿帕替尼片治疗晚期肝癌的研究进展[J]. 国际医药研究前沿, 2020; 4: (1) : 1-6.